• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

These Small-Cap Biotech Stocks Have the Wind at Their Back

After getting a 'win' earlier this week on an acquisition, let's highlight a few similar names in my portfolio.
By BRET JENSEN
May 24, 2023 | 01:30 PM EDT
Stocks quotes in this article: VECT, IRWD, ABCL, BHVN, PFE

On Tuesday I posted a tweet from Kip Herriage on Doug Kass' Daily Diary on Real Money Pro as I thought it was an interesting observation.

Returns of 10 Largest US Co's (from bear mkt lows):

Microsoft +49%
Amazon +43%
Meta +182%
Alphabet +48%
Apple +39%
Berk Hath +26%
NVIDIA +186%
Tesla +88%
Visa +29%
ExxonMobil +32%

Avg. 7 Mo Gain: +72%

The generals are leading.#VRA

— Kip Herriage ���� (@KHerriage) May 23, 2023

What is intriguing is that if you are an optimist about the market, this leads you to be encouraged that the "generals" are leading the recent rally whereas a skeptic would say the rise in the market lacks much breadth.

Small biotech stocks have had the bit in their teeth since the sector successfully tested its June lows in mid-March. An uptick in M&A has helped ignite a rekindling of some animal spirits over the past couple of months.

I was fortunate enough to get a small win earlier this week when VectivBio Holding AG (VECT)  agreed to be purchased by Ironwood Pharmaceuticals (IRWD)  in an all-cash offer with a solid buyout premium.

Today, I will highlight a couple of other small biotech names in my portfolio that seem to have recent momentum.

Let's start with Canada-based AbCellera Biologics Inc. (ABCL) . This developmental concern is focused on the discovery of antibodies, which then can be developed as therapies against a wide spectrum of indications. The company utilizes a proprietary artificial intelligence-driven technology platform to select and develop these antibody candidates.

AbCellera has a fortress balance sheet which will fully fund five years of operations at its current run rate. It also has a diverse pipeline of a dozen and half partnered programs. Its T-cell engager or TCE program looks particularly promising.

The company has seen four "buy" reiterations from analyst firms so far in May and the stock is up 20% over the past week. Indeed, ABCL feels like it may have finally found a hard bottom after falling more than 80% from its IPO price late in 2020. This is a recent addition to my portfolio.

I have already had one successful round trip in Biohaven Ltd. (BHVN) via covered call holdings since it was spun out in late summer of last year. This was part of Pfizer's (PFE) purchase of Biohaven's mother company with the same name. The big drug maker kept that company's migraine assets, which included Nurtec and then spun off the rest of the firm.

The "new" Biohaven has built a candidate pool within its pipeline off its four distinct mechanistic development platforms. The company has two late-stage programs of note. One is targeting Obsessive-Compulsive Disorder or OCD. The other is being evaluated as a potential treatment of spinal muscle atrophy or SMA.

Biohaven also has a large net cash position on its balance sheet and has received positive analyst commentary over the past couple of weeks as well. If development continues to proceed apace, I could see the latest version of Biohaven also being acquired by a larger concern.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long ABCL, BHVN and VECT.

TAGS: Fundamental Analysis | Investing | Small Cap | Biotechnology | Healthcare | U.S. Equity

More from Healthcare

Bearish Bets: 3 Stocks You Should Really Consider Shorting This Week

Bob Lang
May 28, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Why Are CRISPR Therapeutics Charts Saying 'Buy'?

Bruce Kamich
May 15, 2023 1:00 PM EDT

Here's where traders could go long.

Is It Time to Get Back Into CVS Health? Here's a Trade Idea

Stephen Guilfoyle
May 15, 2023 10:30 AM EDT

The fundamentals are not in tip-top shape, and now investors have reduced guidance to deal with.

Bearish Bets: 3 Well-Known Stocks You Should Consider Shorting This Week

Bob Lang
May 14, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:19 PM EDT CHRIS VERSACE

    AAP Podcast: This Company Is Not Going 'Solo'

    Listen in as I talk with the very diversified Solo...
  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login